Clinicopathological features, immunophenotyping, and immunohistochemical biomarkers associated with germline BRCA1/2 variants in breast cancer: a retrospective cohort of 265 patients.

Feifei Huang, Zhongyi Tong, Yi Jiang

Abstract read

In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it

0cells of the map it votes in

0citing papers in PubMed

–field-weighted citation impact

1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Feifei HuangDepartment of Pathology, Shenzhen People's Hospital (The Second Clinical Medical College, Jinan University; The First Affiliated Hospital, Southern University of Science and Technology), Shenzhen, 518020, China.

Zhongyi TongDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China.

Yi JiangDepartment of Pathology, The Second Xiangya Hospital, Central South University, Changsha, 410011, Hunan, China. jiangyi76@csu.edu.cn.

Funding

the Natural Science Foundation of Guangxi Zhuang Autonomous Region No. 2024JJA140129the Natural Science Foundation of Hunan Province No. 2024JJ5478the Natural Science Foundation of Hunan Province No. 2024JJ5498the Scientific Research Project of Hunan Provincial Health Commission No. W20243217

6 · The paper itself

Abstract

Breast cancer (BC) progression and treatment response are influenced by germline BRCA1/2 (gBRCA) variant status. Carrying BRCA1/2 gene variants increases an individual's risk of developing breast cancer. With the advent of poly ADP-ribose polymerase (PARP) inhibitors, these patients may achieve disease control and effective treatment. However, the clinicopathological characteristics and immunophenotypes associated with this gene in breast cancer remain incompletely understood. A total of 265 patients with invasive breast cancer were retrospectively enrolled and tested for gBRCA variants. Germline pathogenic/likely pathogenic BRCA1/2 variants are associated with distinct clinicopathological features, triple-negative breast cancer (TNBC) enrichment, and adverse prognosis. Integrating BRCA1/2 testing with immunohistochemical (IHC) biomarkers (including programmed death-ligand 1(PD-L1) in TNBC) may help refine risk stratification and inform individualized therapy.

Indexed as

Biomarkers, TumorBRCA1 ProteinBRCA2 ProteinBreast NeoplasmsGerm-Line MutationTriple Negative Breast NeoplasmsAdultAgedB7-H1 AntigenFemaleHumansImmunohistochemistryImmunophenotypingMiddle AgedPrognosisRetrospective StudiesB7-H1 AntigenBiomarkers, TumorBRCA1 ProteinBRCA1 protein, humanBRCA2 ProteinBRCA2 protein, humanBreast cancerGermline BRCA1/2p53PD-L1PrognosisTriple-negative breast cancer

Identifiers

PMID42362642

DOI10.1038/s41598-026-57652-6

PMCPMC13569824

What Socratic holds

Textmetadata

Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.